Michael J. Giuliani, M.D. has been appointed vice president of R&D for
Covidien's Pharmaceutical Products and Imaging Solutions. He will lead the R&D organization's efforts to identify and deliver advancements to the pharmaceutical and imaging markets. Dr. Giuliani reports to Timothy R. Wright, president, Pharmaceutical Products and Imaging Solutions.
Dr. Giuliani has more than 25 years of medical experience and is a clinical neurology specialist who has served as a professor in the Department of Clinical Neurology at the University of Pittsburgh. Dr. Giuliani was also the co-director of the National Institutes of Health-sponsored Clinical Research Training Program and a member of the University of Pittsburgh Internal Review Board.
Dr. Giuliani joins the company from Xanodyne Pharmaceuticals, where he was chief medical officer and executive vice president of product development. Prior to that, he was the senior director of clinical neuroscience/ophthalmology at Merck and director of CNS Research at Wyeth.
James L. Young, Ph.D. has joined the company as vice president of R&D operations for Pharmaceutical Products and Imaging Solutions. Dr. Young will guide all planning, operation and monitoring activities for the Pharmaceutical and Imaging R&D organizations. He will manage all R&D support activities for proprietary products, including pharmaceutical development operations and clinical development programs.
Dr. Young also joins the company from Xanodyne Pharmaceuticals, where he was vice president of product development. He has 20 years of experience in the pharmaceutical industry, having served in management, strategic development, sales and scientific roles at companies such as Nexeon, AstraZeneca and Merck.
Ralph A. Heasley, Ph.D. has been appointed vice president of global R&D technology, Pharmaceutical Products. Dr. Heasley will be responsible for overseeing and directing pharmaceutical R&D activities, with a focus on creating better technical products and processes.
Dr. Heasley has more than 30 years of experience in pharmaceutical R&D, having held executive-level and other key positions at Xanodyne, Quintiles, and 3M Pharmaceuticals.
Randel Frazier will continue as vice president, global R&D, Imaging Solutions. He will lead all aspects of imaging development efforts, with an additional focus on exploring new uses for existing imaging capabilities and on developing new products using the company's competencies in radiology, nuclear imaging and contrast delivery systems.
Mr. Frazier has more than 25 years of experience in medical device and pharmaceutical R&D. He joined Tyco Healthcare in 1994 and became vice president, Imaging R&D in 2002. He has also served in R&D, manufacturing, sales and marketing roles for several other companies, including Colorado Medtech, , Gambro and 3M.
Magazine
